Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary... J Clin Immunol (2017) 37:603–612 DOI 10.1007/s10875-017-0424-4 ORIGINAL ARTICLE Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study 1,2 3 4 5 Michael Borte & Isaac R. Melamed & Grazyna Pulka & Barbara Pyringer & 6 7 8 9 Alan P. Knutsen & Hans D. Ochs & Roger H. Kobayashi & Ai Lan Kobayashi & 10 11 12 13 Sudhir Gupta & Magdalena Strach & William Smits & Anna Pituch-Noworolska & James N. Moy Received: 14 March 2017 /Accepted: 18 July 2017 /Published online: 29 July 2017 The Author(s) 2017. This article is an open access publication Abstract ment was associated with a higher rate of upper respiratory Purpose To assess the efficacy and safety of panzyga® (intra- tract infections (RTIs), ear infections, and work/school ab- venous immunoglobulin 10%) in preventing serious bacterial sences, but a lower rate of lower RTIs and fever. Treatment infections (SBIs) in patients with primary immunodeficiency was generally well tolerated; no AE led to treatment with- diseases (PIDs), a prospective, open-label, multicenter, phase drawal or death. 3 study and an open-label extension study were undertaken. Conclusions Overall, the use of panzyga® in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Immunology Springer Journals

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

Loading next page...
 
/lp/springer_journal/efficacy-and-safety-of-human-intravenous-immunoglobulin-10-panzyga-in-3FDdCBMC3p
Publisher
Springer US
Copyright
Copyright © 2017 by The Author(s)
Subject
Biomedicine; Immunology; Infectious Diseases; Internal Medicine; Medical Microbiology
ISSN
0271-9142
eISSN
1573-2592
D.O.I.
10.1007/s10875-017-0424-4
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial